ClinicalTrials.gg
RecruitingNCT07546656Updated May 11, 2026

Prediction of Fluid Responsiveness Using the Femoral Vein-to-Artery Diameter Ratio

An observational study in Fluid Responsiveness, Acute Circulatory Failure and Shock, sponsored by Istanbul University - Cerrahpasa. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Istanbul University - Cerrahpasa · Observational

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

This prospective single-center observational study aims to evaluate whether the ultrasound-measured femoral vein-to-femoral artery diameter ratio can predict fluid responsiveness in mechanically ventilated adult intensive care patients with acute circulatory failure or shock. Only patients who already have PiCCO monitoring as part of routine clinical care and for whom a fluid challenge is clinically indicated will be included. No additional invasive procedure will be performed for study purposes. Cardiac index will be measured with PiCCO before and after administration of 500 mL balanced crystalloid over 10 minutes, and femoral vein and femoral artery diameters will be measured by bedside ultrasonography. Fluid responsiveness will be defined as an increase of more than 10% in cardiac index after fluid administration. The study will assess the diagnostic performance of the femoral vein-to-femoral artery diameter ratio as a practical bedside parameter to support hemodynamic decision-making in critically ill patients.

Read the detailed description

Acute circulatory failure and shock are common conditions in the intensive care unit, and fluid administration remains a key component of hemodynamic management. However, unnecessary fluid loading may worsen tissue edema, oxygenation, and organ function. Therefore, practical bedside tools that help identify fluid-responsive patients are clinically important.

The aim of this study is to evaluate the clinical utility of the ultrasound-measured femoral vein-to-femoral artery diameter ratio in predicting fluid responsiveness in mechanically ventilated adult ICU patients with acute circulatory failure or shock. This is a prospective, single-center, observational study.

No additional invasive intervention will be performed for research purposes. PiCCO monitoring will not be initiated for study reasons; only patients who already have PiCCO monitoring as part of routine ICU management and who are scheduled to undergo a clinically indicated fluid challenge will be enrolled.

Before the fluid challenge, cardiac index will be recorded using PiCCO, and femoral vein and femoral artery diameters will be measured by bedside ultrasonography at the same anatomical level proximal to the femoral artery bifurcation. Each ultrasound measurement will be repeated at least three times, and the mean value will be recorded. A fluid challenge consisting of 500 mL balanced crystalloid administered over 10 minutes will then be performed according to routine clinical care. After the fluid challenge, cardiac index and the femoral vein-to-femoral artery diameter ratio will be reassessed using the same methods.

Fluid responsiveness will be defined as an increase of more than 10% in cardiac index after fluid administration. Responders and non-responders will be compared, and the diagnostic performance of the femoral vein-to-femoral artery diameter ratio will be analyzed.

Demographic data, baseline clinical findings, hemodynamic measurements, and ultrasound measurements will be collected and analyzed. Appropriate descriptive statistics, group comparisons, and diagnostic performance analyses will be used to evaluate the discriminative ability of the femoral vein-to-femoral artery diameter ratio. All data will be de-identified and handled in accordance with patient confidentiality principles.

02

Conditions studied

  • Fluid Responsiveness
  • Acute Circulatory Failure
  • Shock

Browse trials for

Keywords

  • Fluid Responsiveness
  • Shock
  • Acute Circulatory Failure
  • Hemodynamic Monitoring
  • Ultrasonography
  • Femoral Vein
  • Femoral Artery
  • PiCCO
03

In context

Shock

487 studies on the registry are indexed under Shock; 107 are open to participants now.

This study's planned enrollment of 100 is close to the median of 100 across 247 observational studies indexed under Shock.

Browse Shock studies →

Lead sponsor

Istanbul University - Cerrahpasa is the lead sponsor of 699 studies on the registry; 213 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of adult intensive care unit patients with acute circulatory failure or shock who are receiving invasive mechanical ventilation and for whom the responsible intensive care physician has determined a clinical indication for a fluid challenge. Only patients who already have PiCCO monitoring in place as part of routine clinical care and in whom femoral vein and femoral artery ultrasonographic measurements can be obtained will be enrolled.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged 18 years or older
  • Admission to the intensive care unit where the study is being conducted
  • Receiving invasive mechanical ventilation
  • Clinical indication for a fluid challenge due to acute circulatory failure or shock, as determined by the responsible intensive care physician
  • PiCCO monitoring already in place as part of routine clinical care
  • Clinical conditions allowing collection of pre- and post-fluid challenge cardiac index and ultrasonographic measurements
  • Technical feasibility of femoral vein and femoral artery diameter measurements by ultrasonography

Exclusion criteria

Exclusion Criteria:

  • Age younger than 18 years
  • Failure to obtain written from the patient or legally authorized representative before enrollment
  • Absence of PiCCO monitoring as part of routine clinical care or no clinical plan for fluid challenge
  • Inability to complete pre- and post-fluid challenge measurements (e.g., early death, urgent surgery, transfer)
  • Local conditions preventing reliable femoral ultrasonographic assessment, including open wound, infection, dressing, major anatomic obstacle, poor image quality, known femoral vein thrombosis, or severe vascular pathology on the relevant side
  • Conditions likely to significantly impair the reliability of thermodilution measurements (e.g., severe tricuspid regurgitation or significant intracardiac shunt)
  • Major treatment changes during the fluid challenge that preclude comparable measurements (e.g., major vasopressor dose change, major ventilator setting change, new arrhythmia)
  • Missing or inadequate data judged by the investigators to compromise data integrity, including absence of measurements required for the primary outcome
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testUltrasound Measurement of Femoral Vein-to-Femoral Artery Diameter Ratio

    Bedside ultrasonographic measurement of femoral vein and femoral artery diameters at the same anatomical level proximal to the femoral artery bifurcation, with at least three repeated measurements and calculation of the femoral vein-to-femoral artery diameter ratio before and after a clinically indicated fluid challenge.

06

What researchers measure

Primary outcomes

  1. Diagnostic performance of the baseline femoral vein-to-femoral artery diameter ratio for predicting fluid responsiveness

    Diagnostic performance of the baseline ultrasound-measured femoral vein-to-femoral artery diameter ratio in identifying fluid responders, assessed by receiver operating characteristic analysis (area under the curve). Fluid responsiveness will be defined as an increase of more than 10% in cardiac index after administration of 500 mL balanced crystalloid over 10 minutes.

    Time frame: Baseline assessment before fluid challenge, with responder status determined 10 minutes after completion of the fluid challenge

Secondary outcomes

  1. Percent change in cardiac index after fluid challenge

    Percent change in PiCCO-derived cardiac index after administration of 500 mL balanced crystalloid over 10 minutes.

    Time frame: Before fluid challenge and 10 minutes after completion of the fluid challenge

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07546656
Responsible party
mert katılmış (Resident Physician, Department of Anesthesiology and Reanimation, Istanbul University - Cerrahpasa) — Principal investigator
First posted
Apr 23, 2026
Start date
May 1, 2026
Primary completion
Jan 31, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
May 11, 2026

Study contacts

mert katılmış
Contact
mertkatilmis97@gmail.com
+905346430560

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion